- Report
- August 2026
- 160 Pages
Global
From €3023EUR$3,320USD£2,593GBP
€3779EUR$4,150USD£3,241GBP
- Report
- August 2026
- 160 Pages
Global
From €3023EUR$3,320USD£2,593GBP
€3779EUR$4,150USD£3,241GBP
- Report
- June 2026
- 116 Pages
Global
From €4234EUR$4,650USD£3,632GBP
- Report
- July 2025
- 150 Pages
Global
From €5417EUR$5,950USD£4,647GBP
- Report
- December 2024
- 150 Pages
Global
From €5417EUR$5,950USD£4,647GBP
- Report
- August 2025
- 120 Pages
United States
From €3596EUR$3,950USD£3,085GBP
- Report
- October 2023
- 145 Pages
Global
From €2868EUR$3,150USD£2,460GBP
- Report
- October 2023
- 145 Pages
Global
From €2868EUR$3,150USD£2,460GBP
- Report
- November 2023
- 189 Pages
Global
From €4097EUR$4,500USD£3,515GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €2276EUR$2,500USD£1,953GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1138EUR$1,250USD£976GBP
- Report
- December 2024
- 84 Pages
Global
From €3596EUR$3,950USD£3,085GBP
- Report
- February 2024
- 168 Pages
Global
From €7238EUR$7,950USD£6,209GBP
- Report
- July 2023
- 135 Pages
Global
From €6829EUR$7,500USD£5,858GBP
- Report
- July 2023
- 67 Pages
Global
From €3596EUR$3,950USD£3,085GBP
- Report
- May 2024
- 139 Pages
Global
From €2731EUR$2,999USD£2,342GBP
€3641EUR$3,999USD£3,123GBP
- Report
- February 2023
- 70 Pages
Global
From €3182EUR$3,495USD£2,730GBP
- Report
- January 2025
- 200 Pages
Global
From €4548EUR$4,995USD£3,901GBP
- Report
- November 2023
- 140 Pages
Global
From €4052EUR$4,450USD£3,476GBP
- Report
- June 2023
- 204 Pages
Global
From €3278EUR$3,600USD£2,812GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more